dbGaPapplication/xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/release_notes/Release_Notes.phs001709.TP_MetastaticBC.v1.p1.MULTI.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/manifest/manifest_phs001709.TP_MetastaticBC.v1.p1.c1.GRU.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/manifest/Study_Report.phs001709.TP_MetastaticBC.v1.p1.MULTI.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/GapExchange_phs001709.v1.p1.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/pheno_variable_summaries/phs001709.v1.pht009492.v1.p1.CMI_MBC_Subject.var_report.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/pheno_variable_summaries/phs001709.v1.pht009495.v1.CMI_MBC_Sample_Attributes.data_dict.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/pheno_variable_summaries/phs001709.v1.pht009492.v1.CMI_MBC_Subject.data_dict.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/pheno_variable_summaries/phs001709.v1.pht009494.v1.CMI_MBC_Subject_Phenotypes.data_dict.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/pheno_variable_summaries/phs001709.v1.pht009493.v1.CMI_MBC_Sample.data_dict.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/pheno_variable_summaries/phs001709.v1.pht009493.v1.p1.CMI_MBC_Sample.var_report.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/pheno_variable_summaries/phs001709.v1.pht009495.v1.p1.CMI_MBC_Sample_Attributes.var_report.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/pheno_variable_summaries/phs001709.v1.pht009494.v1.p1.CMI_MBC_Subject_Phenotypes.var_report.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/pheno_variable_summaries/varreports_v3.xslftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/dbGaPEx2.1.5.xsdftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001709/phs001709.v1.p1/pheno_variable_summaries/datadict_v2.xslprimaryOK200GenomicCohortBC, metastatic, count, cg5591, breast cancer, cancer of breast, CG5591, carcinoma of breast, LPT, DmelCG5591., NOS, cancer of the breast, breast carcinoma, mammary carcinoma, carcinoma of the breast, cancer, breast, cmi<p>Patients who have ever had a diagnosis of metastatic breast cancer and reside in the US and Canada can choose to enroll themselves directly in the study via <a href="https://www.mbcproject.org">https://www.mbcproject.org</a>. Online informed consent was obtained from each patient. This study is approved by the Dana-Farber Cancer Institute IRB under protocol 15-057B.</p>https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001709Funding Source - Institutional Funding - Broad Institute, Cambridge, MA, USAPrincipal Investigator - Nikhil Wagle, MD - Broad Institute/Dana Farber Cancer Institute, Cambridge, MA, USAdbGaPhttps://www.mbcproject.org/data-releaseHealth Diary, CPD photolyase activity, Ribonucleic, Activity, PhrB photolyase activity, Laboratory, Document, Mail Order, Gene Expression Profile, I-kappa-B-zeta, Xkl-1, Profiles, Tumor, pigmented epithelium, extracted material, dmTAF[[II]]230, KL receptor activity, Health Diaries, Gsfsco1, Medical Transcriptions, responsivity, whole exome sequencing, SCO5, 3, cancer of the breast, SCO1, NUP96, INAP, Research Activity, outer pigmented layer of retina, Gpi-1, Gsfsow3, Laboratory Research, Gsfsco5, epithelium, Non Polyadenylated, RNA Gene Products, SOW3, Postal, Priorities, BC, portion of tissue, AA408868, thymus nucleic acid, Biopsies, TFIID TAF250, ClinicalHistory, cel, Nlk, Diary, neoplasm (disease), Tissue, pigmented retina, W, free, Signatures, DNA cyclobutane dipyrimidine photolyase activity, CA, SUPPRESSOR OF AUXIN RESISTANCE 3, Social, Diaries, Social Medium, Mail-Order, pigment epithelium of retina, cancer of breast, malignant neoplasm, Expression Signature, sample, Transcriptomes, pigmented retina epithelium, Bs, Services, Double-Stranded DNA, Research Priority, Twitter Messaging, deoxyribonucleic acids, DNAn, Sl, NK/GPI, Gpi, PRE, Web 2.0, malignancy, dTAF[[II]]230, Data Set, ribose nucleic acid, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, Expression Profiles, ribonucleic acids, TAF200, Salivas, Research Priorities, Tr-kit, Double-Stranded, TAFII-250, pigmented retinal epithelium, TAF250/230, (Deoxyribonucleotide)n+m, Gene Expression, PBT, TAFII250, count, mOC-X, retinal pigment, Expression Signatures, Ribonukleinsaeure, Distributions, tissue portion, kl1-A, dipyrimidine photolyase (photosensitive), pentosenucleic acids, NOS, simple tissue, Ribonucleic acids, breast carcinoma, NK|GPI, KIT, desoxyribose nucleic acid, Expression Profile, retinal pigment layer, Transcriptome Profiles, Research and Development, tyrosine-protein kinase Kit, Acid, pbt, ORG, Org, Consent Form, Twitter, retinal pigmented epithelium, IkappaBzeta, Molecule possessing ankyrin repeats induced by lipopolysaccharide, Mail-Orders, Gpi1-r, Gpi1-s, kit, IKBZ, Gpi1-t, CG17603, TAF[[II]], Activities, metastatic, phr A photolyase activity, Health, DNA-photoreactivating enzyme, breast cancer, Patient, Taf250, SR3-5, ds DNA, DNA, carcinoma of the breast, cancer, Bglap-rs1, TAF230, Gpi1s, Informed Consent Forms, krk1, d230, DNS, genomic profiling data, (Deoxyribonucleotide)n, AI461847, Transcriptome Profile, cell type cancer, Goal, SCF receptor activity, Gene, dTAFII250, Mails, photoreactivating enzyme activity, IL-1 inducible nuclear ankyrin-repeat protein, EfW1, Deoxyribonucleic acids, deoxyribodipyrimidine photolyase activity, stratum pigmentosum retinae, scfr, Deoxyribonucleic Acid, Publication, dmTAF1, Taf230, resistance, saliva molecularis, Gene Products, Pgi, stratum pigmentosa retinae, Web, Documents, Distribution, neoplasm, Medical, SCFR, malignant tumour, TAF250, portion of blood, Consent Document, study, reactivity, Transcription, Fdc, Postal Services, Taf200, WES, MOS3, dTAF[[II]]250, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, PRECOCIOUS, Research, Gpi-1r, malignant growth, clinical information, cell, Gpi-1s, Profile, Phi, saliva atomaris, Gpi-1t, F23A5.3, study., Double Stranded, Taf1p, mammary carcinoma, Deoxyribonucleic acid, Informed Consent Document, Medical Record, Non-Polyadenylated RNA, genomic profiling, dTAF250, 2.0s, Informed, Clients, Development and Research, (Deoxyribonucleotide)m, TAF, Messaging, F23A5_3, proto-oncogene c-Kit, targeted exome capture, data, RNA, TAF[[II]]250, IkB-zeta, Transcriptome, whole blood, carcinoma of breast, malignant, vertebrate blood, DNAn+1, Informed Consent, MAIL, l(3)84Ab, RNS, BG:DS00004.13, MF, Amf, Web 2.0s, RGD1310834, Client, Records, Cell, dTAF230, stratum pigmentosum (retina), MODIFIER OF SNC1, Priority, MT, Media, KIT ligand receptor activity, p230, yeast nucleic acid, malignant neoplasm (disease), Informed Consent Form, Mail Distribution, Gene Expression Signatures, Research Activities, deoxyribonucleic photolyase activity, TAF[[II]]250/230, TFIID, Gene Expression Signature, Medical Transcription, ds-DNA, NK, XKrk1, Taf[[II]]250, ribonucleic acid, c-KIT, primary cancer, RPE, TAF[[II]]230, photolyase activity, Transcriptions, Non Polyadenylated RNA, Consent Documents, Non-Polyadenylated, patient, TAF[II]250, Ribonucleic Acid, CD117, Record, retinal pigment epithelium, malignant tumor, sample population, p. pigmentosa retinae, c-kit, DmelCG17603, C-Kit, Service, malignant neoplastic disease, salivary gland secretion, Gene Expression Profiles, Ssm, xkl-1, Desoxyribonukleinsaeure, Mail, Informed Consent Documents, deoxyribonucleate pyrimidine dimer lyase (photosensitive), sailva normalis, response, Signature, Mail Distributions, breast, TAF1falseCount Me In: Metastatic Breast Cancer Project (CMI-MBCproject)<p><u>Count Me In - The Metastatic Breast Cancer Project: A Patient-Driven Research Initiative to Accelerate Metastatic Breast Cancer Research</u></p> <p>The Metastatic Breast Cancer Project (MBCproject; mbcproject.org) is a research study that directly engages patients with metastatic breast cancer via social media and advocacy groups and empowers them to accelerate cancer research by sharing their samples and clinical information. The goal is to create a publicly available dataset of genomic, molecular, clinical, and patient-reported data to enable research. Patients in the US or Canada may register online. Registered patients are sent an online consent form that asks for permission to obtain and analyze their medical records, tumor tissue, saliva, and blood samples. Once enrolled, patients are sent a saliva kit and asked to mail back a saliva sample, which is used to extract germline DNA. Study staff contact participants&#39; medical providers and obtain medical records and a portion of their stored tumor biopsies. Patients may be asked to mail in a blood sample, which is used to extract cell free DNA (cfDNA). Whole exome sequencing (WES) is performed on tumor DNA, germline DNA, and cfNDA; transcriptome sequencing is performed on tumor RNA. Clinically annotated genomic data are used to study specific patient cohorts (including outliers) and to identify mechanisms of response and resistance to therapies. All de-identified data, including genomic, clinical, and patient-reported data, are shared via public databases on a pre-publication and recurring basis as it is generated. Study updates are shared with participants regularly.</p>2018-11-272018-10-04phs001709Carcinoma